Review of the literature on patient satisfaction with early medical abortion using mifepristone and misoprostol

References

• American College of Obstetricians and Gynecologists. Medical Management of Abortion (ACOG Practice Bulletin;no. 67). (2005).
   Google Scholar
• Jones RK, Kooistra K. Abortion incidence and access to services in the United States, 2008. Perspect. Sex Reprod. Health43(1), 41–50 (2011).
   PubMed Web of Science ®Google Scholar
• Finer LB, Wei J. Effect of mifepristone on abortion access in the United States. Obstet. Gynecol.114(3), 623–630 (2009).
   PubMedGoogle Scholar
• Ben Attia M. The Tunisian Experience with Medical Abortion and Family Planning Evolution Since 1965 (2010) (Powerpoint presentation).
   Google Scholar
• Honkanen H, Von Hertzen H. Users’ perspectives on medical abortion in Finland. Contraception65(6), 419–423 (2002).
   PubMed Web of Science ®Google Scholar
• Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Am. J. Obstet. Gynecol.182(6), 1292–1299 (2000).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception64(2), 81–85 (2001).
   PubMed Web of Science ®Google Scholar
• Teal SB, Dempsey-Fanning A, Westhoff C. Predictors of acceptability of medication abortion. Contraception75(3), 224–229 (2007).
   PubMed Web of Science ®Google Scholar
• Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: the impact of sociodemographic characteristics on the acceptability of mifepristone–misoprostol abortion. J. Am. Med. Womens Assoc.55(3 Suppl.), 177–182 (2000).
   PubMedGoogle Scholar
• Teal SB, Harken T, Sheeder J, Westhoff C. Efficacy, acceptability and safety of medication abortion in low-income, urban Latina women. Contraception80(5), 479–483 (2009).
   PubMed Web of Science ®Google Scholar
• Akin A, Blum J, Ozalp S et al. Results and lessons learned from a small medical abortion clinical study in Turkey. Contraception70(5), 401–406 (2004).
   PubMed Web of Science ®Google Scholar
• Bracken H. Home administration of misoprostol for early medical abortion in India. Int. J. Gynaecol. Obstet.108(3), 228–232 (2010).
   PubMedGoogle Scholar
• Elul B, Hajri S, Ngoc Nn et al. Can women in less-developed countries use a simplified medical abortion regimen? Lancet357(9266), 1402–1405 (2001).
   PubMed Web of Science ®Google Scholar
• Hajri S, Blum J, Gueddana N et al. Expanding medical abortion in Tunisia: women’s experiences from a multi-site expansion study. Contraception70(6), 487–491 (2004).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet. Gynecol.103(5 Pt 1), 851–859 (2004).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Fielding Sl, Westhoff C et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA284(15), 1948–1953 (2000).
   PubMed Web of Science ®Google Scholar
• Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. J. Am. Med. Womens Assoc.55(3 Suppl.), 169–172 (2000).
   PubMedGoogle Scholar
• Fielding SL, Edmunds E, Schaff EA. Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women’s experiences. Perspect. Sex Reprod. Health34(1), 34–40 (2002).
   PubMed Web of Science ®Google Scholar
• Ganatra B, Kalyanwala S, Elul B, Coyaji K, Tewari S. Understanding women’s experiences with medical abortion: in-depth interviews with women in two Indian clinics. Global Public Health5(4), 335–347 (2010).
   PubMed Web of Science ®Google Scholar
• Harvey SM, Beckman LJ, Roberts Branch M. The relationship of contextual factors to women’s perceptions of medical abortion. Health Care Women Int.23(6–7), 654–665 (2002).
   PubMedGoogle Scholar
• Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am. J. Obstet. Gynecol.183(2 Suppl.), S44–S53 (2000).
   PubMedGoogle Scholar
• Shah R, Baji S, Kalgutkar S. Attitudes about medical abortion among Indian women. Int. J. Gynaecol. Obstet.89(1), 69–70 (2005).
   PubMed Web of Science ®Google Scholar
• Shochet T, Trussell J. Determinants of demand: method selection and provider preference among US women seeking abortion services. Contraception77(6), 397–404 (2008).
   PubMedGoogle Scholar
• Simonds W, Ellertson C, Springer K, Winikoff B. Abortion, revised: participants in the U.S. clinical trials evaluate mifepristone. Soc. Sci. Med.46(10), 1313–1323 (1998).
   PubMed Web of Science ®Google Scholar
• Winikoff B. Acceptability of medical abortion in early pregnancy. Fam. Plann. Perspect.27(4), 142–148, 185 (1995).
   PubMedGoogle Scholar
• Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception61(1), 41–46 (2000).
   PubMed Web of Science ®Google Scholar
• Mamers PM, Lavelle AL, Evans AJ, Bell SM, Rusden JR, Healy DL. Women’s satisfaction with medical abortion with RU486. Med. J. Aust.167(6), 316–317 (1997).
   PubMedGoogle Scholar
• Knudsen UB. First trimester abortion with mifepristone and vaginal misoprostol. Contraception63(5), 247–250 (2001).
   PubMedGoogle Scholar
• Akin A, Dabash R, Dilbaz B et al. Increasing women’s choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone. Eur. J. Contracept. Reprod. Health Care14(3), 169–175 (2009).
   PubMed Web of Science ®Google Scholar
• Coyaji K, Elul B, Krishna U et al. Mifepristone–misoprostol abortion: a trial in rural and urban Maharashtra, India. Contraception66(1), 33–40 (2002).
   PubMed Web of Science ®Google Scholar
• Ho PC. Women’s perceptions on medical abortion. Contraception74(1), 11–15 (2006).
   PubMed Web of Science ®Google Scholar
• Honkanen H, Piaggio G, Hertzen H et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. BJOG111(7), 715–725 (2004).
   PubMed Web of Science ®Google Scholar
• Ngoc NT, Winikoff B, Clark S et al. Safety, efficacy and acceptability of mifepristone–misoprostol medical abortion in Vietnam. Int. Fam. Plan. Perspect.25(1), 10–14 (1999).
   Google Scholar
• Raghavan S, Comendant R, Digol I, Ungureanu S, Friptu V. Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days’ gestational age: a randomized controlled trial of sublingual and oral misoprostol. Contraception79(2), 84–90 (2009).
   PubMed Web of Science ®Google Scholar
• Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone–misoprostol. Results of a large multicenter trial in the United States. Mifepristone Clinical Trials Group. Arch. Fam. Med.7(4), 360–366 (1998).
   PubMedGoogle Scholar
• Winikoff B, Sivin I, Coyaji K et al. The acceptability of medical abortion in China, Cuba and India. Int. Fam. Plan. Perspect.23(2), 73–78 (1997).
   Google Scholar
• Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception66(4), 247–250 (2002).
   PubMed Web of Science ®Google Scholar
• Shannon C, Wiebe E, Jacot F et al. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG113(6), 621–628 (2006).
   PubMed Web of Science ®Google Scholar
• Elul B, Ellertson C, Winikoff B, Coyaji K. Side effects of mifepristone–misoprostol abortion versus surgical abortion. Data from a trial in China, Cuba, and India. Contraception59(2), 107–114 (1999).
   PubMed Web of Science ®Google Scholar
• Beckman LJ, Harvey SM. Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women. Womens Health Issues7(4), 253–262 (1997).
   PubMed Web of Science ®Google Scholar
• Winikoff B, Dzuba IG, Creinin MD et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet. Gynecol.112(6), 1303–1310 (2008).
   PubMed Web of Science ®Google Scholar
• Mundle S, Elul B, Anand A. Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center. Contraception76, 66–70 (2007).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Dicenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception71(1), 22–25 (2005).
   PubMed Web of Science ®Google Scholar
• Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int. J. Gynaecol. Obstet.99(Suppl. 2), S160–S167 (2007).
   PubMed Web of Science ®Google Scholar
• Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. Contraception74(1), 26–30 (2006).
   PubMed Web of Science ®Google Scholar
• Tang OS, Xu J, Cheng L, Lee SW, Ho PC. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. Hum. Reprod.17(7), 1738–1740 (2002).
   PubMed Web of Science ®Google Scholar
• Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: drug absorption and uterine response. Obstet. Gynecol.108(3 Pt 1), 582–590 (2006).
   PubMed Web of Science ®Google Scholar
• Singh KC, Ummat S, Rajaram S, Goel N. First trimester abortion with mifepristone and three doses of sublingual misoprostol: a pilot study. Aust. NZJ Obstet. Gynaecol.45(6), 495–498 (2005).
   PubMed Web of Science ®Google Scholar
• Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur. J. Obstet. Gynecol. Reprod. Biol.123(1), 87–91 (2005).
   PubMed Web of Science ®Google Scholar
• Middleton T, Schaff E, Fielding SL et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception72(5), 328–332 (2005).
   PubMed Web of Science ®Google Scholar
• Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur. J. Contracept. Reprod. Health Care5(3), 171–176 (2000).
   PubMedGoogle Scholar
• Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG111(9), 1001–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Kiran U, Amin P, Penketh RJ. Self-administration of vaginal misoprostol after mifepristone for termination of pregnancy: patient acceptability. J. Obstet. Gynaecol.26(7), 679–681 (2006).
   PubMedGoogle Scholar
• Perriera LK, Reeves MF, Chen BA, Hohmann HL, Hayes J, Creinin MD. Feasibility of telephone follow-up after medical abortion. Contraception81(2), 143–149 (2010).
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Flett GM, Templeton A. Home self-administration of misoprostol for medical abortion up to 56 days’ gestation. J. Fam. Plann. Reprod. Health Care31(3), 189–192 (2005).
   PubMedGoogle Scholar
• Lohr PA, Wade J, Riley L, Fitzgibbon A, Furedi A. Women’s opinions on the home management of early medical abortion in the UK. J. Fam. Plann. Reprod. Health Care36(1), 21–25 (2010).
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Dow J, Flett GM, Templeton A. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contraception68(5), 335–338 (2003).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Schwartz JL, Pymar HC, Fink W. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. BJOG108(5), 469–473 (2001).
   PubMedGoogle Scholar
• Ngoc NT, Nhan VQ, Blum J, Mai TT, Durocher JM, Winikoff B. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. BJOG111(8), 814–819 (2004).
   PubMed Web of Science ®Google Scholar
• Von Hertzen H, Huong NT, Piaggio G et al. Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG117(10), 1186–1196 (2010).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet. Gynecol.109(4), 885–894 (2007).
   PubMed Web of Science ®Google Scholar
• Ganatra B, Bygdeman M, Phan BT, Nguyen DV, Vu ML. From research to reality: the challenges of introducing medical abortion into service delivery in Vietnam. Reprod. Health Matters12(24 Suppl.), 105–113 (2004).
   PubMed Web of Science ®Google Scholar
• Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B. Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. Eur. J. Contracept. Reprod. Health Care10(3), 184–191 (2005).
   PubMed Web of Science ®Google Scholar
• Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K. Acceptability of home-use of misoprostol in medical abortion. Contraception70(5), 387–392 (2004).
   PubMed Web of Science ®Google Scholar
• Bracken H, Gliozheni O, Kati K et al. Mifepristone medical abortion in Albania: results from a pilot clinical research study. Eur. J. Contracept. Reprod. Health Care11(1), 38–46 (2006).
   PubMed Web of Science ®Google Scholar
• Karki C, Pokharel H, Kushwaha A, Manandhar D, Bracken H, Winikoff B. Acceptability and feasibility of medical abortion in Nepal. Int. J. Gynaecol. Obstet.106(1), 39–42 (2009).
   PubMed Web of Science ®Google Scholar
• Shannon CS, Winikoff B, Hausknecht R et al. Multicenter trial of a simplified mifepristone medical abortion regimen. Obstet. Gynecol.105(2), 345–351 (2005).
   PubMed Web of Science ®Google Scholar
• Blum J, Hajri S, Chelli H, Mansour FB, Gueddana N, Winikoff B. The medical abortion experiences of married and unmarried women in Tunis, Tunisia. Contraception69(1), 63–69 (2004).
   PubMed Web of Science ®Google Scholar
• Faucher P, Baunot N, Madelenat P. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients]. Gynecol. Obstet. Fertil.33(4), 220–227 (2005).
   PubMedGoogle Scholar
• Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception59(1), 1–6 (1999).
   PubMed Web of Science ®Google Scholar
• Fielding SL, Schaff EA. Social context and the experience of a sample of U.S. women taking RU-486 (mifepristone) for early abortion. Qual. Health Res.14(5), 612–627 (2004).
   PubMed Web of Science ®Google Scholar
• Winikoff B. Acceptability of first-trimester medical abortion. In: Modern Methods of Inducing Abortion. Baird D, Grimes D, Look PV (Eds). Blackwell Science Ltd, Oxford, UK, 145–169 (1995).
   Google Scholar
• Ngoc NT, Blum J, Raghavan S et al. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception83(5), 410–417 (2011).
   PubMedGoogle Scholar
• Lynd K. The acceptability and feasibility of an alternative to a routine follow-up visit after medical abortion in Vietnam. Presented at: Meeting of the Association for Reproductive Health Professionals. Atlanta, GA, USA, 22–25 September 2010.
   Google Scholar
• Clark W, Bracken H, Tanenhaus J, Schweikert S, Lichtenberg ES, Winikoff B. Alternatives to a routine follow-up visit for early medical abortion. Obstet. Gynecol.115(2 Pt 1), 264–272 (2010).
   PubMed Web of Science ®Google Scholar
• Bjørge L, Johnsen Sl, Midboe G et al. Early pregnancy termination with mifepristone and misoprostol in Norway. Acta Obstet. Gynecol. Scand.80(11), 1056–1061 (2001).
   PubMed Web of Science ®Google Scholar
• Suhonen S, Heikinheimo O, Tikka M, Haukkamaa M. The learning curve is rapid in medical termination of pregnancy – first-year results from the Helsinki area. Contraception67(3), 223–227 (2003).
   PubMed Web of Science ®Google Scholar
• Jerbi M, Hidar S, Sahraoui W et al. [Mifepristone 100 mg for early medical abortion]. J. Gynecol. Obstet. Biol. Reprod. (Paris)34(3 Pt 1), 257–261 (2005).
   PubMedGoogle Scholar
• Kallner HK, Fiala C, Stephansson O, Gemzell-Danielsson K. Home self-administration of vaginal misoprostol for medical abortion at 50–63 days compared with gestation of below 50 days. Hum. Reprod.25(5), 1153–1157 (2010).
   PubMed Web of Science ®Google Scholar
• Tran N, Jang M, Yong S. Feasibility, efficacy, safety, and acceptability of mifepristone–misoprostol for medical abortion in the Democratic People’s Republic of Korea. Int. J. Obstet. Gynecol.109, 209–212 (2010).
   PubMed Web of Science ®Google Scholar
• Du M, Ying Y, Zheng H, Zhen W, Ni R. A comparison study of oral RU486/Cytotec and vacuum aspiration for termination of early pregnancy. Reprod. Contracept.7(2), 103–110 (1996).
   Google Scholar
• Winikoff B, Sivin I, Coyaji Kj et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone–misoprostol versus surgical abortion. Am. J. Obstet. Gynecol.176(2), 431–437 (1997).
   PubMed Web of Science ®Google Scholar
• Coyaji K. Early medical abortion in India: three studies and their implications for abortion services. J. Am. Med. Womens Assoc.55(3 Suppl.), 191–194 (2000).
   Google Scholar
• Coyaji K, Krishna U, Ambardekar S et al. Are two doses of misoprostol after mifepristone for early abortion better than one? BJOG114(3), 271–278 (2007).
   PubMed Web of Science ®Google Scholar
• Guest J, Chien P, Thomson M, Kosseim Ml. Randomised controlled trial comparing efficacy of same day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36- to 48-hour protocol. BJOG112(10), 1457 (2007).
   Google Scholar
• Cheng L. Medical abortion in early pregnancy: experience in China. Contraception74(1), 61–65 (2006).
   PubMed Web of Science ®Google Scholar